Holen Sie sich die Stockscreener-App
1.02
3.77%
-0.04
Handel nachbörslich:
1.02
Schlusskurs vom Vortag:
$1.06
Offen:
$1.07
24-Stunden-Volumen:
252.88K
Relative Volume:
0.57
Marktkapitalisierung:
$83.13M
Einnahmen:
$3.91M
Nettoeinkommen (Verlust:
$-206.53M
KGV:
-0.4109
EPS:
-2.4825
Netto-Cashflow:
$-167.78M
1W Leistung:
-5.56%
1M Leistung:
+20.00%
6M Leistung:
-26.62%
1J Leistung:
-42.37%
1-Tages-Spanne:
$1.01
$1.08
1-Wochen-Bereich:
$1.01
$1.12
52-Wochen-Spanne:
$0.841
$2.08
I Mab Adr Stock (IMAB) Company Profile
Vergleichen Sie IMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
1.02 | 83.13M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-09 | Eingeleitet | Siebert Williams Shank | Buy |
| 2021-06-02 | Eingeleitet | Daiwa Securities | Buy |
| 2021-03-15 | Eingeleitet | Needham | Buy |
| 2021-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-25 | Eingeleitet | Piper Sandler | Overweight |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-12 | Eingeleitet | China Renaissance | Buy |
| 2020-02-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
I Mab Adr Aktie (IMAB) Neueste Nachrichten
I-Mab Chairman plans $2 million ADS purchase - Investing.com India
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - MSN
I-Mab names Sean Fu as new CEO - Investing.com India
Invitation: Vallourec Q3 2024 Results ReleaseConference Call on Friday, November 15, 2024 - The Manila Times
I-Mab ADR (NASDAQ: IMAB) Stock: Investors Need To Know This - Stocks Register
Would I Buy Spectral AI Inc (NASDAQ: MDAI) Stock At Any Time In The Future? - Stocks Register
If You Don’t Buy Hub Cyber Security Ltd (NASDAQ: HUBC) Now, You’ll Kick Yourself Later - Stocks Register
Itau Unibanco Holding S.A. ADR (NYSE: ITUB) Still Pointing Upwards - Stocks Register
Is Veritone Inc’s (NASDAQ:VERI) Stock On The Decline? - Stocks Register
Cisco Systems, Inc. (NASDAQ: CSCO): What’s Next After The Stock Plunge? - Stocks Register
Should This Give Tandem Diabetes Care Inc (NASDAQ: TNDM) Investors Sleepless Nights? - Stocks Register
Kinross Gold Corp. (NYSE: KGC) Investors Should Be Worried About This. - Stocks Register
Where Do Analysts See Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Heading? - Stocks Register
Not A Good News For Keycorp (NYSE: KEY): The Stock Could Go Down -34.98 Percent More - Stocks Register
Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading - MSN
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
IMAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Company’s Banking Shares: Up -42.43% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
It makes sense and dollars to buy I-Mab ADR (IMAB) stock - SETE News
Ratio Revelations: I-Mab ADR (IMAB)’s Financial Metrics in the Spotlight - The Dwinnex
I-Mab ADR (IMAB) Stock: From Low to High in 52 Weeks - The InvestChronicle
IMAB’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com
I-Mab reveals Phase 1 data for lung cancer treatment - Investing.com
Federal Hill Taphouse & Kitchen abruptly closes - WPRI.com
I-Mab ADR (IMAB)’s stock price in review: A technical analysis - US Post News
There is no doubt that I-Mab ADR (IMAB) ticks all the boxes. - SETE News
Earnings call: I-MAB Biopharma discusses pipeline progress and financials - Investing.com India
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates - PR Newswire
I-Mab appoints new chairman and interim CEO - Investing.com
Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature.com
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Effects of a monoclonal antibody against (pro)renin receptor on gliomagenesis - Nature.com
Market Brief: Will the December CPI Report Help Further Tame Inflation Fears? - Morningstar
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
The Cheapest Stock in the World - Morningstar.ca
10 of the Cheapest Stocks of 2022 - Morningstar
Why Are Some China Healthcare Stocks Up 50%? - HK.Morningstar.com
Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature.com
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
Markets Brief: How High Can Mortgage Rates Go? - Morningstar
New 5-Star Stocks - Morningstar
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
10 biotechs to know in China - FiercePharma
I-Mab Announces Upcoming Participation at September Conferences - BioSpace
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study - Yahoo Finance
I-MabADR to Host Earnings Call - AccessWire
I-Mab (IMAB) Stock Price, News & Analysis - MarketBeat
Finanzdaten der I Mab Adr-Aktie (IMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):